Subject(s)
Humans , Female , Adult , Uterine Cervical Neoplasms/complications , Uterine Cervical Neoplasms , Cervix Uteri/pathology , Cervix Uteri , Fluorodeoxyglucose F18 , Neoplasm Metastasis/pathology , Neoplasm Metastasis , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapy , Positron Emission Tomography Computed Tomography/methods , Positron Emission Tomography Computed Tomography/trends , Positron Emission Tomography Computed TomographySubject(s)
Carcinoma/diagnosis , Carcinoma/secondary , Fluorodeoxyglucose F18 , Multimodal Imaging , Muscle Neoplasms/diagnosis , Muscle Neoplasms/secondary , Positron-Emission Tomography , Radiopharmaceuticals , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/secondary , Subcutaneous Tissue , Tomography, X-Ray Computed , Uterine Cervical Neoplasms/pathology , Chemoradiotherapy , Female , Humans , Middle Aged , Uterine Cervical Neoplasms/therapyABSTRACT
BACKGROUND: Krukenberg tumor is a metastatic ovarian tumor with primary focus usually seen in the gastrointestinal tract. Metastatic involvement of the ovary is an uncommon manifestation of malignancy. We report a [18F]-fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography (FDG PET/CT) appearance of solitary unilateral ovarian metastasis in a 44-year-old woman with a history of mucinous adenocarcinoma type of gastric carcinoma. Total hysterectomy with bilateral salpingo-oophorectomy was performed. Histopathological verification determined metastasis of mucinous adenocarcinoma with components of signet-ring cell carcinoma in the right ovary.
Subject(s)
Adenocarcinoma, Mucinous/secondary , Fluorodeoxyglucose F18 , Multimodal Imaging/methods , Ovarian Neoplasms/secondary , Positron-Emission Tomography , Radiopharmaceuticals , Stomach Neoplasms/pathology , Tomography, X-Ray Computed , Adenocarcinoma, Mucinous/diagnostic imaging , Adult , Female , Humans , Ovarian Neoplasms/diagnostic imagingSubject(s)
Adrenal Gland Neoplasms/secondary , Carcinoma, Neuroendocrine/secondary , Fluorodeoxyglucose F18 , Multimodal Imaging , Ovarian Neoplasms/pathology , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed , Adrenal Gland Neoplasms/diagnostic imaging , Aged , Carcinoma, Neuroendocrine/diagnostic imaging , Carcinoma, Neuroendocrine/drug therapy , Carcinoma, Neuroendocrine/surgery , Combined Modality Therapy , Female , Humans , Hysterectomy , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Ovariectomy , SalpingectomyABSTRACT
PURPOSE: The aim of the current study was to determine the diagnostic accuracy of whole-body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in detecting carcinoma of unknown primary (CUP). MATERIALS AND METHODS: A total of 7,636 patients were investigated by FDG-PET/CT examinations at our Institution. We retrospectively evaluated the file records of 432 patients who were referred to FDG PET/CT imaging with a diagnosis of cancer of unknown primary, and included 316 of the patients with histopathologic verification at the final diagnosis. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were calculated. The Kaplan-Meier test was used for survival analysis. Median survival rate was calculated to evaluate the prognostic value of the FDG-PET/ CT findings. RESULTS: In the search for a primary, FDG-PET/CT findings correctly diagnosed lesions as the site of the primary true positive in 238 cases, 10 findings diagnosed no site of a primary and none was subsequently proven true negative, 12 diagnoses were false positive and 56 were false negative. The sensitivity of FDG-PET/CT is 81% and the specificity 45%. Positive predictive value, negative predictive value and diagnostic accuracy were 95%, 15% and 78%, respectively. CONCLUSIONS: Whole-body FDG-PET/CT imaging is proven to be useful method in the search for the primary focus and metastases in patients with cancer of unknown primary.
